Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 8/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3775217 | 0.89 | CYP11B1 (0.48) | LRRK2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL3770171 | 0.83 | PLK4 (0.46) | LRRK2EGFR | |
| SCHEMBL3775083 | 0.83 | AXL (0.46) | LRRK2 | |
| SCHEMBL3773018 | 0.82 | CYP1A2 (0.42) | LRRK2EGFRCYP19A1GRM4 | |
| SCHEMBL3775370 | 0.80 | LRRK2 (0.63) | LRRK2GRM4 | |
| SCHEMBL3775329 | 0.80 | LRRK2 (0.61) | LRRK2EGFRGRM4 | |
| SCHEMBL3771247 | 0.80 | LRRK2 (0.43) | LRRK2EGFRMAPK8GRM4 | |
| SCHEMBL3766347 | 0.78 | CDK1 (0.43) | LRRK2EGFRGRM4 | |
| SCHEMBL3764047 | 0.78 | CYP11B1 (0.48) | EGFRCYP19A1CYP11B1CYP11B2GRM4 | |
| SCHEMBL3763899 | 0.77 | GRM4 (0.51) | LRRK2EGFRGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | LRRK2 2208/4885EGFR 102/4885CYP19A1 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.